Atlas Trials

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Clinical trial NCT05039515 · TERMINATED

Trial details

NCT number
NCT05039515
Sponsor
Clementia Pharmaceuticals Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Fibrodysplasia Ossificans Progressiva
Start date
2021-12-01
Primary completion
2026-03-27
Enrollment
113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.